| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GNS |
| Uniprot No | P15586 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 37-552aa |
| 氨基酸序列 | VFGVAAGTRRPNVVLLLTDDQDEVLGGMTPLKKTKALIGEMGMTFSSAYV PSALCCPSRASILTGKYPHNHHVVNNTLEGNCSSKSWQKIQEPNTFPAIL RSMCGYQTFFAGKYLNEYGAPDAGGLEHVPLGWSYWYALEKNSKYYNYTL SINGKARKHGENYSVDYLTDVLANVSLDFLDYKSNFEPFFMMIATPAPHS PWTAAPQYQKAFQNVFAPRNKNFNIHGTNKHWLIRQAKTPMTNSSIQFLD NAFRKRWQTLLSVDDLVEKLVKRLEFTGELNNTYIFYTSDNGYHTGQFSL PIDKRQLYEFDIKVPLLVRGPGIKPNQTSKMLVANIDLGPTILDIAGYDL NKTQMDGMSLLPILRGASNLTWRSDVLVEYQGEGRNVTDPTCPSLSPGVS QCFPDCVCEDAYNNTYACVRTMSALWNLQYCEFDDQEVFVEVYNLTADPD QITNIAKTIDPELLGKMNYRLMMLQSCSGPTCRTPGVFDPGYRFDPRLMF SNRGSVRTRRFSKHLLVDHHHHHH |
| 预测分子量 | 58 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GNS重组蛋白的3篇参考文献示例(注：部分内容为模拟示例，实际文献需根据具体研究补充)：
---
1. **文献名称**: "Expression and Characterization of Recombinant Human N-acetylglucosamine-6-sulfatase (GNS) in CHO Cells for Enzyme Replacement Therapy"
**作者**: Smith, J., et al.
**摘要**: 本研究报道了在CHO细胞中高效表达重组人GNS蛋白的方法，并验证了其酶活性。实验表明，纯化的重组GNS能有效降解底物硫酸肝素，为粘多糖贮积症III型的酶替代疗法提供了潜在治疗方案。
2. **文献名称**: "Structural Insights into the Catalytic Mechanism of GNS through X-ray Crystallography"
**作者**: Li, X., & Wang, Y.
**摘要**: 通过X射线晶体学解析了重组GNS蛋白的三维结构，揭示了其底物结合位点及催化机制，为基于结构的药物设计(如小分子激活剂或稳定剂)提供了理论基础。
3. **文献名称**: "Optimization of Recombinant GNS Production in Pichia pastoris for Industrial-scale Applications"
**作者**: García, R., et al.
**摘要**: 研究利用毕赤酵母系统规模化生产重组GNS蛋白，通过优化发酵条件和纯化工艺，显著提高了蛋白产量和稳定性，降低了生产成本，推动其向临床转化。
---
**说明**：若需实际文献，建议通过PubMed或Google Scholar搜索关键词“recombinant GNS protein”、“GNS enzyme replacement therapy”获取最新研究。GNS相关研究多集中于粘多糖贮积症III型(MPS III)的治疗开发。
**Background of GNS Recombinant Proteins**
Glycosaminoglycan N-sulfotransferase (GNS) is a critical enzyme involved in the biosynthesis of heparan sulfate (HS), a sulfated glycosaminoglycan (GAG) essential for cellular signaling, extracellular matrix organization, and molecular interactions. GNS catalyzes the transfer of sulfate groups to specific N-acetylglucosamine residues in HS precursors, a modification critical for HS’s structural diversity and functional specificity. Dysregulation of GNS activity is linked to lysosomal storage disorders, such as mucopolysaccharidosis type IIID (Sanfilippo syndrome D), highlighting its biological and clinical relevance.
Recombinant protein technology has enabled the production of GNS in heterologous systems (e.g., *E. coli*, mammalian cells) to study its enzymatic mechanisms and therapeutic potential. Recombinant GNS proteins are generated by cloning the *GNS* gene into expression vectors, followed by purification using affinity chromatography. Mammalian systems, such as HEK293 or CHO cells, are often preferred to ensure proper post-translational modifications and functional activity.
The availability of recombinant GNS has advanced research in HS-related pathologies and drug discovery. For instance, it serves as a tool to investigate HS sulfation patterns in cancer metastasis, viral entry, and neurodegenerative diseases. Additionally, recombinant GNS is explored in enzyme replacement therapies (ERT) for genetic disorders caused by GNS deficiency. Challenges remain in optimizing its stability, delivery, and immunogenicity for clinical applications.
Overall, GNS recombinant proteins bridge basic research and translational medicine, offering insights into GAG biology and paving the way for novel treatments targeting HS-associated diseases.
×
